← Back to Screener
Cerus Corp (CERS)
Price$2.71
Value ScoreD
Growth ScoreB
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)46.05%
Price vs S&P 500 (4W)3.84%
VGM Score60.61
Market Capitalization$543.00M
All Metrics
P/CF (Annual)112.26x
Book Value / Share (Quarterly)$0.34
P/TBV (Annual)11.14x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)7.48%
Cash Flow / Share (Quarterly)$-0.01
Price vs S&P 500 (YTD)23.40%
Gross Margin (TTM)58.42%
Net Profit Margin (TTM)-3.90%
EPS (TTM)$-0.05
10-Day Avg Trading Volume2.35M
EPS Excl Extra (TTM)$-0.05
Revenue Growth (5Y)15.41%
EPS (Annual)$-0.08
ROI (Annual)-10.55%
Gross Margin (Annual)59.86%
Net Profit Margin (5Y Avg)-18.80%
Cash / Share (Quarterly)$0.40
Revenue Growth QoQ (YoY)22.60%
ROA (Last FY)-7.04%
Revenue Growth TTM (YoY)18.41%
EBITD / Share (TTM)$-0.01
ROE (5Y Avg)-52.08%
Operating Margin (TTM)-1.30%
Cash Flow / Share (Annual)$0.01
P/B Ratio8.04x
P/B Ratio (Quarterly)5.18x
Net Income / Employee (Annual)$-56,800
EV / Revenue (TTM)2.45x
Net Interest Coverage (TTM)-0.59x
ROA (TTM)-4.38%
EV / EBITDA (TTM)44.81x
EPS Incl Extra (Annual)$-0.08
Current Ratio (Annual)1.73x
Quick Ratio (Quarterly)1.02x
3-Month Avg Trading Volume2.05M
52-Week Price Return96.38%
EV / Free Cash Flow (Annual)541.50x
Revenue / Employee (TTM)$890,300
Tangible BV / Share (Quarterly)$0.62
P/S Ratio (Annual)2.32x
Asset Turnover (Annual)1.05x
52-Week High$3.15
Operating Margin (5Y Avg)-15.13%
EPS Excl Extra (Annual)$-0.08
CapEx CAGR (5Y)18.15%
Tangible BV CAGR (5Y)2.02%
26-Week Price Return53.98%
Quick Ratio (Annual)1.12x
13-Week Price Return32.84%
Total Debt / Equity (Annual)1.31x
Current Ratio (Quarterly)1.63x
Enterprise Value$599.98M
Revenue / Share Growth (5Y)11.98%
Asset Turnover (TTM)1.12x
Book Value / Share Growth (5Y)-11.54%
Revenue / Employee (Annual)$850,200
Inventory Turnover (Annual)1.99x
Pretax Margin (Annual)-6.54%
Cash / Share (Annual)$0.43
3-Month Return Std Dev89.90%
Gross Margin (5Y Avg)60.54%
Net Income / Employee (TTM)$-34,700
ROE (Last FY)-24.33%
Net Interest Coverage (Annual)-0.03x
EPS Basic Excl Extra (Annual)$-0.08
P/FCF (TTM)108.88x
Receivables Turnover (TTM)8.80x
EV / Free Cash Flow (TTM)512.50x
Total Debt / Equity (Quarterly)1.26x
EPS Incl Extra (TTM)$-0.05
Receivables Turnover (Annual)7.77x
ROI (TTM)-6.51%
P/S Ratio (TTM)2.22x
Pretax Margin (5Y Avg)-18.64%
Revenue / Share (Annual)$1.23
Tangible BV / Share (Annual)$0.62
Price vs S&P 500 (52W)72.01%
Year-to-Date Return31.55%
5-Day Price Return-4.58%
EPS Normalized (Annual)$-0.08
ROA (5Y Avg)-15.79%
Net Profit Margin (Annual)-6.68%
Month-to-Date Return-10.86%
Cash Flow / Share (TTM)$-0.26
EBITD / Share (Annual)$-0.04
Operating Margin (Annual)-3.71%
LT Debt / Equity (Annual)0.63x
P/CF (TTM)206.31x
ROI (5Y Avg)-24.05%
LT Debt / Equity (Quarterly)0.48x
EPS Basic Excl Extra (TTM)$-0.05
P/TBV (Quarterly)11.14x
P/B Ratio (Annual)6.16x
Inventory Turnover (TTM)1.86x
Pretax Margin (TTM)-3.76%
Book Value / Share (Annual)$0.33
Price vs S&P 500 (13W)24.59%
Beta1.80x
P/FCF (Annual)490.07x
Revenue / Share (TTM)$1.26
ROE (TTM)-15.36%
52-Week Low$1.15
vGradeD
gGradeB
mGradeB
vgmGradeB
Show chart for
Earnings Surprise History
Q1 26-0.01est. -0.04
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.00
4.00
4.00
4.00
Industry Peers — Surgical & Medical Instruments(138)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
CERSCerus Corp | D | B | B | $2.71 |
| SYKStryker Corporation | C | C | C | $305.66 |
| MMM3M Company | C | F | C | $153.76 |
| BSXBoston Scientific Corp. | C | B | D | $48.55 |
| MDLNMedline Inc. Class A common stock | C | D | D | $33.61 |
| BDXBecton, Dickinson and Co. | B | C | C | $151.16 |
| RMDResMed Inc. | C | B | C | $196.04 |
| DXCMDexCom, Inc. | C | B | C | $72.86 |
| WSTWest Pharmaceutical Services, Inc. | D | C | B | $314.50 |
| SOLVSolventum Corporation | C | D | B | $81.01 |
| PENPenumbra, Inc. | F | C | B | $320.53 |
About
Cerus Corp manufactures pathogen-reduction systems for blood transfusion safety, primarily through its INTERCEPT platelet and plasma products. The company operates globally across the United States, Europe, the Middle East, and select international markets. Blood safety represents its sole business focus and revenue driver.